H2U, Taiwan's premier digital health brand, has announced another successful round of funding this year after receiving recognition from South Korean medical laboratory powerhouse SCL (Seoul Clinical Laboratories). The partnership is solidified through a strategic investment from InnoTherapy Inc., an affiliated company under the SCL Group.

Under the agreement, InnoTherapy and H2U will provide healthcare services and products, and data platform development for corporate and individual healthcare management. AhealthZ and H2U will jointly import and export medical devices, reagents, and other SCL Group products.

The collaboration will see the partners assist H2U in introducing the H2U eXamine health assessment platform and the H2U pano personal digital health platform to the Korean healthcare industry while promoting their adoption within the SCL Group's health examination facilities. In turn, H2U will support SCL in bringing outstanding Korean medical testing technology to Taiwan.

"Looking ahead, we shall broaden and strengthen our international presence via strategic partnerships and utilising SCL's expansive footprints in Southeast and Northeast Asia. This includes diagnostic tests and health exam facilities in Indonesia and Mongolia," said Saxon Chen, CEO of H2U.

A Foxconn Group spin-off established in 2013, H2U is planning entry into Taiwan's capital market in the upcoming year with the vision of becoming Asia's leading digital health unicorn.